Quick Answer
LEXICON PHARMACEUTICALS, INC. reported R&D Expense of $61.12 million for fiscal year 2025.
LEXICON PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $61.12M | -27.7% |
| 2024 | $84.48M | +43.5% |
| 2023 | $58.89M | +11.5% |
| 2022 | $52.82M | -4.1% |
| 2021 | $55.05M | -64.2% |
| 2020 | $153.62M | +67.1% |
| 2019 | $91.92M | -8.3% |
| 2018 | $100.24M | -34.1% |
| 2017 | $152.22M | -7.2% |
| 2016 | $163.97M | +72.3% |
| 2015 | $95.19M | +6.6% |
| 2014 | $89.28M | -0.4% |
| 2013 | $89.68M | +8.6% |
| 2012 | $82.57M | -10.1% |
| 2011 | $91.83M | +16.9% |
| 2010 | $78.52M | -3.3% |
| 2009 | $81.24M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $18.76M | -27.2% | +19.1% |
| June 30, 2025 | $15.75M | -10.7% | +2.9% |
| March 31, 2025 | $15.30M | +6.5% | -40.6% |
| September 30, 2024 | $25.78M | +46.8% | +46.1% |
| June 30, 2024 | $17.64M | +21.3% | +22.8% |
| March 31, 2024 | $14.37M | +19.5% | -18.1% |
| September 30, 2023 | $17.56M | +66.3% | +20.7% |
| June 30, 2023 | $14.54M | +8.9% | +20.9% |
- LEXICON PHARMACEUTICALS, INC. showed a decrease of -27.7% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, LEXICON PHARMACEUTICALS, INC.’s r&d expense has declined by 24.8% (from $81.24 million to $61.12 million).
- The most recent figure is from LEXICON PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: